TiGenix gets European patent relating to adipose-derived stem cell composition

TiGenix, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced that the European Patent Office (EPO) has issued European Patent EP2292736 relating to an adipose-derived stem cell composition.

Category One, Showcase, status, Uncategorized, What's Hot